Clinical Trial Update: Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase II randomized, double-blind study evaluating HRS-9813 for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Progressive Fibrosing Interstitial Lung Disease

Drugs mentioned

• HRS-9813

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: IPF and PPF | Phase 2 | Status: RECRUITING